Tabata T - Search Results

1

Atherogenic lipoproteins in end-stage renal disease.

Shoji T, Ishimura E, Inaba M, Tabata T, Nishizawa Y. Shoji T, et al. Among authors: tabata t. Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S30-3. doi: 10.1053/ajkd.2001.27393. Am J Kidney Dis. 2001. PMID: 11576918 Review.

2

Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis.

Shoji T, Nishizawa Y, Kawagishi T, Tanaka M, Kawasaki K, Tabata T, Inoue T, Morii H. Shoji T, et al. Among authors: tabata t. Atherosclerosis. 1997 Jun;131(2):229-36. doi: 10.1016/s0021-9150(97)00054-3. Atherosclerosis. 1997. PMID: 9199276

3

Plasma leptin level and its relationship with body composition in hemodialysis patients.

Nishizawa Y, Shoji T, Tanaka S, Yamashita M, Morita A, Emoto M, Tabata T, Inoue T, Morii H. Nishizawa Y, et al. Among authors: tabata t. Am J Kidney Dis. 1998 Apr;31(4):655-61. doi: 10.1053/ajkd.1998.v31.pm9531182. Am J Kidney Dis. 1998. PMID: 9531182

4

Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients.

Shoji T, Nishizawa Y, Kawagishi T, Kawasaki K, Taniwaki H, Tabata T, Inoue T, Morii H. Shoji T, et al. Among authors: tabata t. J Am Soc Nephrol. 1998 Jul;9(7):1277-84. doi: 10.1681/ASN.V971277. J Am Soc Nephrol. 1998. PMID: 9644639 Clinical Trial.

5

Leptin in peritoneal dialysate from continuous ambulatory peritoneal dialysis patients.

Tsujimoto Y, Shoji T, Tabata T, Morita A, Emoto M, Nishizawa Y, Morii H. Tsujimoto Y, et al. Among authors: tabata t. Am J Kidney Dis. 1999 Nov;34(5):832-8. doi: 10.1016/S0272-6386(99)70039-9. Am J Kidney Dis. 1999. PMID: 10561138

6

Atherogenic lipoprotein changes in diabetic nephropathy.

Shoji T, Emoto M, Kawagishi T, Kimoto E, Yamada A, Tabata T, Ishimura E, Inaba M, Okuno Y, Nishizawa Y. Shoji T, et al. Among authors: tabata t. Atherosclerosis. 2001 Jun;156(2):425-33. doi: 10.1016/s0021-9150(00)00673-0. Atherosclerosis. 2001. PMID: 11395040

7

Plasma 1,5-anhydroglucitol concentration in patients with end-stage renal disease with and without diabetes mellitus.

Emoto M, Tabata T, Inoue T, Nishizawa Y, Morii H. Emoto M, et al. Among authors: tabata t. Nephron. 1992;61(2):181-6. doi: 10.1159/000186868. Nephron. 1992. PMID: 1630543

8

Circulating bone Gla protein in end-stage renal disease determined by newly developed two-site immunoradiometric assay.

Nakatsuka K, Miki T, Nishizawa Y, Tabata T, Inoue T, Morii H, Ogata E. Nakatsuka K, et al. Among authors: tabata t. Contrib Nephrol. 1991;90:147-54. doi: 10.1159/000420137. Contrib Nephrol. 1991. PMID: 1959340

9

Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients.

Nishizawa Y, Shoji T, Emoto M, Kawasaki K, Konishi T, Tabata T, Inoue T, Morii H. Nishizawa Y, et al. Among authors: tabata t. Clin Nephrol. 1995 Apr;43(4):268-77. Clin Nephrol. 1995. PMID: 7606882 Clinical Trial.

10

Acute renal failure associated with minimal change nephrotic syndrome in an elderly adult.

Morita A, Ishimura E, Tabata T, Shoji S, Inoue T, Nishizawa Y, Morii H. Morita A, et al. Among authors: tabata t. Osaka City Med J. 1994 Jul;40(1):37-42. Osaka City Med J. 1994. PMID: 9309942

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,003 results

Search Page

Filters